Valeant Pharmaceuticals International, Inc. (VRX) Upgraded to “Strong-Buy” by Vetr Inc.

Vetr upgraded shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) from a buy rating to a strong-buy rating in a research report report published on Thursday morning. The brokerage currently has $14.26 price objective on the specialty pharmaceutical company’s stock.

A number of other equities research analysts have also issued reports on the company. Zacks Investment Research lowered Valeant Pharmaceuticals International from a hold rating to a strong sell rating in a research note on Thursday, July 13th. ValuEngine lowered Valeant Pharmaceuticals International from a buy rating to a hold rating in a research note on Friday, September 1st. Wells Fargo & Co dropped coverage on Valeant Pharmaceuticals International in a research note on Sunday, July 30th. Cantor Fitzgerald reaffirmed a buy rating and issued a $23.00 target price on shares of Valeant Pharmaceuticals International in a research note on Tuesday, August 29th. Finally, BidaskClub raised Valeant Pharmaceuticals International from a hold rating to a buy rating in a research note on Thursday, June 29th. Five analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of Hold and an average target price of $17.56.

Shares of Valeant Pharmaceuticals International (NYSE:VRX) traded down 2.80% during trading on Thursday, hitting $12.13. The company’s stock had a trading volume of 9,259,123 shares. Valeant Pharmaceuticals International has a one year low of $8.31 and a one year high of $24.30. The stock’s market cap is $4.23 billion. The company has a 50-day moving average price of $13.84 and a 200-day moving average price of $13.58.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.97 by $0.08. The business had revenue of $2.23 billion for the quarter, compared to analyst estimates of $2.23 billion. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The company’s quarterly revenue was down 7.7% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.88) EPS. Equities analysts predict that Valeant Pharmaceuticals International will post $3.89 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Valeant Pharmaceuticals International, Inc. (VRX) Upgraded to “Strong-Buy” by Vetr Inc.” was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://ledgergazette.com/2017/10/20/valeant-pharmaceuticals-international-inc-vrx-upgraded-to-strong-buy-by-vetr-inc.html.

In related news, Director Schutter Richard U. De purchased 10,000 shares of the stock in a transaction that occurred on Monday, August 21st. The stock was purchased at an average cost of $14.33 per share, for a total transaction of $143,300.00. Following the acquisition, the director now owns 77,479 shares in the company, valued at $1,110,274.07. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.87% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Paulson & CO. Inc. increased its holdings in Valeant Pharmaceuticals International by 12.5% in the 2nd quarter. Paulson & CO. Inc. now owns 21,813,400 shares of the specialty pharmaceutical company’s stock valued at $377,372,000 after purchasing an additional 2,428,900 shares in the last quarter. Vanguard Group Inc. increased its holdings in Valeant Pharmaceuticals International by 4.2% in the 2nd quarter. Vanguard Group Inc. now owns 7,274,717 shares of the specialty pharmaceutical company’s stock valued at $125,853,000 after purchasing an additional 294,643 shares in the last quarter. Bank of Montreal Can increased its holdings in Valeant Pharmaceuticals International by 9.8% in the 2nd quarter. Bank of Montreal Can now owns 6,330,670 shares of the specialty pharmaceutical company’s stock valued at $109,521,000 after purchasing an additional 564,215 shares in the last quarter. CIBC World Markets Inc. increased its holdings in Valeant Pharmaceuticals International by 2.3% in the 2nd quarter. CIBC World Markets Inc. now owns 3,741,413 shares of the specialty pharmaceutical company’s stock valued at $64,726,000 after purchasing an additional 83,592 shares in the last quarter. Finally, Chou Associates Management Inc. increased its holdings in Valeant Pharmaceu

A number of other equities research analysts have also issued reports on the company. Zacks Investment Research lowered Valeant Pharmaceuticals International from a hold rating to a strong sell rating in a research note on Thursday, July 13th. ValuEngine lowered Valeant Pharmaceuticals International from a buy rating to a hold rating in a research note on Friday, September 1st. Wells Fargo & Co dropped coverage on Valeant Pharmaceuticals International in a research note on Sunday, July 30th. Cantor Fitzgerald reaffirmed a buy rating and issued a $23.00 target price on shares of Valeant Pharmaceuticals International in a research note on Tuesday, August 29th. Finally, BidaskClub raised Valeant Pharmaceuticals International from a hold rating to a buy rating in a research note on Thursday, June 29th. Five analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of Hold and an average target price of $17.56.

Shares of Valeant Pharmaceuticals International (NYSE:VRX) traded down 2.80% during trading on Thursday, hitting $12.13. The company’s stock had a trading volume of 9,259,123 shares. Valeant Pharmaceuticals International has a one year low of $8.31 and a one year high of $24.30. The stock’s market cap is $4.23 billion. The company has a 50-day moving average price of $13.84 and a 200-day moving average price of $13.58.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.97 by $0.08. The business had revenue of $2.23 billion for the quarter, compared to analyst estimates of $2.23 billion. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The company’s quarterly revenue was down 7.7% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.88) EPS. Equities analysts predict that Valeant Pharmaceuticals International will post $3.89 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Valeant Pharmaceuticals International, Inc. (VRX) Upgraded to “Strong-Buy” by Vetr Inc.” was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://ledgergazette.com/2017/10/20/valeant-pharmaceuticals-international-inc-vrx-upgraded-to-strong-buy-by-vetr-inc.html.

In related news, Director Schutter Richard U. De purchased 10,000 shares of the stock in a transaction that occurred on Monday, August 21st. The stock was purchased at an average cost of $14.33 per share, for a total transaction of $143,300.00. Following the acquisition, the director now owns 77,479 shares in the company, valued at $1,110,274.07. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.87% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Paulson & CO. Inc. increased its holdings in Valeant Pharmaceuticals International by 12.5% in the 2nd quarter. Paulson & CO. Inc. now owns 21,813,400 shares of the specialty pharmaceutical company’s stock valued at $377,372,000 after purchasing an additional 2,428,900 shares in the last quarter. Vanguard Group Inc. increased its holdings in Valeant Pharmaceuticals International by 4.2% in the 2nd quarter. Vanguard Group Inc. now owns 7,274,717 shares of the specialty pharmaceutical company’s stock valued at $125,853,000 after purchasing an additional 294,643 shares in the last quarter. Bank of Montreal Can increased its holdings in Valeant Pharmaceuticals International by 9.8% in the 2nd quarter. Bank of Montreal Can now owns 6,330,670 shares of the specialty pharmaceutical company’s stock valued at $109,521,000 after purchasing an additional 564,215 shares in the last quarter. CIBC World Markets Inc. increased its holdings in Valeant Pharmaceuticals International by 2.3% in the 2nd quarter. CIBC World Markets Inc. now owns 3,741,413 shares of the specialty pharmaceutical company’s stock valued at $64,726,000 after purchasing an additional 83,592 shares in the last quarter. Finally, Chou Associates Management Inc. increased its holdings in Valeant Pharmaceuticals International by 29.7% in the 2nd quarter. Chou Associates Management Inc. now owns 3,053,843 shares of the specialty pharmaceutical company’s stock valued at $53,030,000 after purchasing an additional 700,000 shares in the last quarter. Hedge funds and other institutional investors own 50.44% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply